Chongqing Lummy Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 397.38 million compared to CNY 605.36 million a year ago. Revenue was CNY 406.43 million compared to CNY 611.97 million a year ago.

Net loss was CNY 49.07 million compared to net income of CNY 32.39 million a year ago. Basic loss per share from continuing operations was CNY 0.0465 compared to basic earnings per share from continuing operations of CNY 0.0347 a year ago. Diluted loss per share from continuing operations was CNY 0.0465 compared to diluted earnings per share from continuing operations of CNY 0.0347 a year ago.